In addition to genetic changes, surrogate marker of PI3K pathway activation, like phosphorylation of AKT, denote increased flux through the signaling pathway and therefore may indicate PI3K inhibitor sensitivity in some cancer models investigated [32, 33]. This evidence concerns the gene AKT1 and cancer.